This is an old revision of this page, as edited by Jytdog(talk | contribs) at 21:32, 16 March 2016(Undid revision 710395604 by 92.26.129.100 (talk) remove content added by sock of blocked user Nuklear per REVERTBAN). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 21:32, 16 March 2016 by Jytdog(talk | contribs)(Undid revision 710395604 by 92.26.129.100 (talk) remove content added by sock of blocked user Nuklear per REVERTBAN)
Bitopertin is a glycine transporter 1 (GlyT1) inhibitor that increases levels of the neurotransmitterglycine by inhibiting its reuptake from the synaptic cleft. Glycine acts as a required co-agonist along with glutamate at N-methyl-D-aspartate (NMDA) receptors. Dysfunction of NMDA receptors may play a key role in the pathogenesis of schizophrenia and modulation of glutamatergic signalling via increased concentrations of glycine in the synaptic cleft may help potentiate NMDA receptor function and improve the symptoms of schizophrenia.[4]
In a phase II proof-of-concept study patients on bitopertin experienced a significant improvement in the change of the Negative Symptom Factor Score from baseline within 8 weeks (from −4.86 in the placebo group to −6.65 in the treatment group, p<0.05, per-protocol population). In addition, 83% of patients on bitopertin described an improvement of negative symptoms on the CGI-I1 vs 66% on placebo (p<0.05, per-protocol population).[5]
In January 2014, Roche reported that bitopertin failed to meet its endpoints in two phase III trials assessing its efficacy in reducing negative symptoms of schizophrenia.[2] Subsequently, in April 2014, Roche announced that it was discontinuing all of its phase III trials of bitopertin for schizophrenia except for one.[2]
Though Roche has largely ceased its studies of bitopertin for schizophrenia, it is also investigating the drug in the treatment of obsessive-compulsive disorder (OCD), and is continuing its development for this indication.[3] As of August 2014, bitopertin is in phase II clinical trials for OCD.[3]
^Glycine Transporter Type 1 (GLYT1) Inhibitor RG1678: Positive Results of the Proof-of-Concept Study for the Treatment of Negative Symptoms in Schizophrenia, Umbricht D. et al., ACNP 2010
